Celltrion announced on the 13th that it has applied to the MFDS for an item license for the “Donerion patch” for the treatment of Alzheimer's dementia jointly developed with Icure.

Donerion patch (Donepezil) is a product jointly developed by bio-venture Icure and Celltrion. In June 2017, after Icure developed and completed the non-clinical and phase 1 clinical trials, it signed a joint domestic copyright contract with Celltrion. Together with Icure, we conducted phase 3 clinical trials in about 400 patients with mild and moderate dementia in 4 countries including Korea, Taiwan, Australia, and Malaysia.

Donerion patch is an IMD developed by attaching the oral Donepezil once a day twice a